| SPECIALTY-PHARMACIES |
SPECIALTY-PHARMACIES |
90%
|
Two U.S. customers (namely specialty pharmacies) accounted for $290.9 million, or 77%, of our revenues for the year ended December 31, 2025, and $227.7 million, or 77%, of our revenues for the year e… |
| ALMAC-GROUP |
ALMAC-GROUP |
85%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from MRK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming’s global medical strategy, including clinical d… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from SNYN… |
| SNYNF |
Sanofi |
72%
|
r clinical trials and meet demand for our products could be impacted. We depend on third-party manufacturers for the production of rhC1INH for commercial supply and for use in clinical trials of RUCO… |
| ZLDPF |
Zealand Pharma A/S |
72%
|
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PHAR graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PHAR graph: . Anurag Relan has been an integr… |
| ZLDPF |
Zealand Pharma A/S |
72%
|
. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming’s global medical strategy, including clinical d… |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
ting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which im… |
| C-ORGANIZATIONAL-STRUCTURE-PHARMING-GROUP |
C-ORGANIZATIONAL-STRUCTURE-PHARMING-GROUP |
62%
|
ting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which im… |
| EXPERT-GROUP |
EXPERT-GROUP |
62%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
| F-14-BIOLOGICAL-ASSETS-THE-GROUP |
F-14-BIOLOGICAL-ASSETS-THE-GROUP |
62%
|
ents. The resulting accounting estimates will, by definition, seldom equal the related actual results. The main estimates and assumptions that have a risk of causing an adjustment to the carrying amo… |
| LEASES-THE-GROUP |
LEASES-THE-GROUP |
62%
|
sfied at a point in time (typically for promises to transfer goods to a customer) or over time (typically for promises to transfer services to a customer). For a performance obligation satisfied over… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
endors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations. Misc… |
| YUNGJIN-PHARM-CO-LTD |
YUNGJIN-PHARM-CO-LTD |
62%
|
ly remained uninterrupted across all commercial markets. C) Joenja® manufacturing Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as… |
